Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

News Releases

  •   Email
  •   Print
  •   Share

  • Dana-Farber Cancer Institute and the Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, will work together to create novel molecular probes for non-invasive imaging in cancer research, drug development and patient care.

Tags: BasicResearch

  • Dana-Farber Cancer Institute and Diichi Sankyo Company, Limited announced a preclinical research collaboration focused on lung cancer.

Tags: LungCancer

  • Researchers from Dana-Farber Cancer Institute and partnering oncology practices across the United States and Canada are testing whether weight loss prevents women with breast cancer from a recurrence. Nestlé Health Science is donating OPTIFAST® nutritionally complete, low calorie meal replacements to help women in the newly launched Breast Cancer Weight Loss (BWEL) study realize their weight loss goals.

Tags: BreastCancer, Prevention

  • The PARP inhibitor niraprib as maintenance therapy for women with recurrent platinum-sensitive high grade ovarian cancer has shown delay of cancer progression. Progression free survival benefit applies regardless of whether or not tumors have BRCA mutations or other DNA-repair deficiencies.

Tags: OvarianCancer

  • Dana-Farber Cancer Institute and Lifespan leadership have signed a memorandum of understanding to form a partnership that will advance cancer treatment and expand research. The details will be finalized early next year.

Tags: Partnerships

  • Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists have found that CML stem cells die in response to inhibition of a protein called Ezh2. Drugs that target the protein are currently being tested in clinical trials for other cancers.

Tags: BasicResearch, Genetics, Leukemia

  • William G. Kaelin Jr., MD, professor in the Department of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, has been named a winner of the 2016 Lasker Award for Basic Medical Research by the Albert and Mary Lasker Foundation.

Tags: Honors

  • Dana-Farber Cancer Institute investigators report they have discovered a type of immune antibody that can rapidly evolve to neutralize a wide array of influenza virus strains – including those the body hasn’t yet encountered.

Tags: Influenza

  • Combining two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), for advanced melanoma appears to increase survival rate over that achieved with a single agent, according to a new study.

Tags: Melanoma, Immunotherapy

  • The plumes of vapor exhaled by e-cigarette users may look like pure mist and exude a fruity aroma, but a new study led by Dana-Farber Cancer Institute researchers suggests that most people are unaware that the vapor contains more than water and may include potentially harmful substances such as formaldehyde.

Tags: LungCancer

Showing 1-10 of 721 items